Nkarta, Inc.

National University of Singapore

James Barnaby Trager

Alexandra Leida Liana Lazetic

Chao Guo

Luxuan Guo Buren

Ivan Ho Chan

Mira Tohmé

Dario Campana

See Voon Seow

Shyam Sashikant Masrani

Jun Hao Leong

Noriko Shimasaki

Katherine Jamboretz

Ivan Chan

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.

Immune cells comprising truncated NKG2D chimeric receptors

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.

Genetically modified natural killer cells for CD70-directed cancer immunotherapy

Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapy

Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.

Cancer immunotherapy using CD19-directed chimeric antigen receptors

Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Growing community of inventors

Albany, CA, United States of America

James Barnaby Trager